학술논문
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
Document Type
Article
Author
Madorsky Rowdo, F.P.; Nguyen, J.; Elemento, O.; Davis, M.B.; Martin, M.L.; Xiao, G.; Bargonetti, J.; Khramtsova, G.F.; Olopade, O.I.; Martini, R.; Stonaker, B.; Gyan, K.K.; Newman, L.; Boateng, R.; Oppong, J.K.; Adjei, E.K.; Awuah, B.; Aitpillah, F.S.; Ankomah, K.; Osei-Bonsu, E.B.; Kyei, I.; Adinku, M.O.; Altorki, N.K.; Cheng, E.; Hoda, S.; Ginter, P.S.
Source
In: Cancer Letters . (Cancer Letters, 1 March 2024, 584)
Subject
Language
English
ISSN
18727980
03043835
03043835